Conference Abstracts : [6734]
Collection home page

Abstracts for conference papers, posters, or presentations.

Browse
in this collection
Subscribe to this collection to receive daily e-mail notification of new additions RSS Feed RSS Feed RSS Feed
Collection's Items (Sorted by Submit Date in Descending order): 161 to 180 of 6734
< previous   next >
PreviewIssue DateTitleAuthor(s)
24-Feb-2026Safety and efficacy of obicetrapib in patients at high cardiovascular risk.Nicholls S.J. ; Nelson A.J.; Ditmarsch M.; Kastelein J.J.P.; Ballantyne C.M.; Ray K.K.; Navar A.M.; Nissen S.E.; Harada-Shiba M.; Hsieh A.
24-Feb-2026Food-specific CD4+ FOXP3+ regulatory t cells identify delayed-hypersensitivity allergies and food triggers in pediatric patients.Poloni C.; Sze A.; Nguyen J.; Giles E. ; Steiner T.; Cook L.
24-Feb-2026Impact of cholesteryl ester transfer protein inhibitor, obicetrapib, on lipoprotein(a) levels: pooled data from phase iii clinical trials.Nicholls S.J. ; Ray K.K.; Szarek M.; Ditmarsch M.; Kling D.; Hsieh A.; Nelson A.J.; Davidsond M.H.; Kasteleind J.J.P.
25-Feb-2026STOPPFrail Medication Use in Frail Residents of Nursing Homes: A Comparison Across Four Countries in Asia, Oceania and Europe.J Liau S.; Zhao M.; Hamada S.; Gutierrez-Valencia M.; Jadczak A.D.; Li L.; Martinez-Velilla N.; Sakata N.; Fu P.; Visvanathan R.; Lalic S.; Roncal-Belzunce V.
27-Feb-2026INTERIM RESULTS from ASSURE: A PHASE 3B SAFETY STUDY of ACALABRUTINIB in PATIENTS with CHRONIC LYMPHOCYTIC LEUKEMIA.Opat S. ; Awan F.; Fogliatto L.; Nikitin E.; Czerwinski J.; Silva R.S.; Jujjavarapu S.; Samoilova O.; Dartigeas C.; Tran H.T.T.; De La Serna J.; Banerji V.; Mayer L.M.; Hart J.; Von Tresckow J.; Poulsen C.B.; Eom K.-S.; Merli M.; John E.; Munley J.; Hakre S.; Hermann R.; Niemann C.
27-Feb-2026IN VITRO MODELLING of beta0-THALASSAEMIA: A CELLULAR PLATFORM ENABLING EXPERIMENTAL and THERAPEUTIC INVESTIGATIONS.Vadolas J. ; Nualkaew T.; Tee H.; Glaser A.; Phuwakanjana P.; Vilcassim S.; Jearawiriyapaisarn N.; Svasti S.; Leboulch P.; Payen E.; Grigoriadis G. 
27-Feb-2026ES-3000, A WNT/ beta CATENIN/INFLAMMASOME PATHWAY INHIBITOR COMBINED with ORAL DECITABINE/CEDAZURIDINE(ASTX727) for PATIENTS with MYELODYSPLASIA.Enjeti A.; Ramamoorthy S.; Hiwase D.; Butcher B.; Kollipara S.; Wei A.H.; Shortt J. 
27-Feb-2026BLINATUMOMAB AS CONSOLIDATION in A PAEDIATRIC PROTOCOL LEADS to HIGH RATES of ENDCONSOLIDATION MRD NEGATIVITY and EXCELLENT OUTCOMES in AYA ALL-FINAL RESULTS of the ALLG ALL09 <<sUBLIME>> STUDY.Greenwood M.; Gangatharan S.; Osborn M.; Ng A.; Fleming S.; Fedele P. ; Trahair T.; Casey J.; Mapp S.; Cheung C.; Armytage T.; Henderson M.; Sutton R.; McCloud P.; Button P.; Larsen S.; Presgrave P.; Kwan J.; Bennett S.; Fong C.Y.; Yeung D.; White D.; Dalla-Pozza L.
27-Feb-2026PEMBROLIZUMAB PLUS the ANTI-LAG-3 ANTIBODY FAVEZELIMAB for ANTI-PD-1-NAIVE RELAPSED or REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA: AN UPDATED ANALYSIS of A PHASE 1/2 STUDY.Johnson N.; Lavie D.; Borchmann P.; Gregory G. ; Herrera A.F.; Minuk L.; Vucinic V.; Armand P.; Avigdor A.; Gasiorowski R.; Herishanu Y.; Keane C.; Kuruvilla J.; West R.M.; Pillai P.; Marinello P.; Timmerman J.
27-Feb-2026THE DEFINITION and USE of BULK DISEASE in PHASE 3 LYMPHOMA TRIALS: A COMPREHENSIVE LITERATURE REVIEW.Wang L. ; Chung E.; Wellard C.; Barraclough A.; Campbell B.; Chong G.; Di Ciaccio P.; Gregory G. ; Hapgood G.; Johnston A.; Tam C.; Opat S. ; Wood E.; McQuilten Z. ; Hawkes E.A.
27-Feb-2026IMMUNOPHENOTYPTIC ANALYSIS of PBL from beta-THALASSEMIA/HEMOGLOBIN e PATIENTS FOLLOWING HYDROXYUREA THERAPY.Thubthed R.; Siriworadetkun S.; Thiengtavor C.; Paiboonsukwong K.; Fucharoen S.; Pattanapanyasat K.; Vadolas J. ; Svasti S.; Chaichompoo P.
27-Feb-2026CLINICAL BENEFIT of LUSPATERCEPT in TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS with VERY LOW-, LOW-OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES in the COMMANDS TRIAL.Santini V.; Zeidan A.M.; Platzbecker U.; Della Porta M.G.; Garcia-Manero G.; Li J.; Kreitz S.; Pozharskaya V.; Rose S.; Lai Y.; Aggarwal B.; Valcarcel D.; Fenaux P.; Shortt J. ; Komrokji R.S.
27-Feb-2026TARGETING DYSREGULATION of IRON HOMEOSTASIS in MDS MICE with AN OPTIMISED GALNACCONJUGATED TMPRSS6 SIRNA.Vadolas J. ; Vilcassim S.; Nualkaew T.; Thubthed R.; Kysenius K.; Crouch P.; Dames S.; Eisermann M.; Martinez A.; Schaeper U.; Grigoriadis G. 
27-Feb-2026BGB-11417-203, AN ONGOING, PHASE 2 STUDY of SONROTOCLAX (BGB-11417), A NEXT-GENERATION BCL2 INHIBITOR, in PATIENTS with WALDENSTROM MACROGLOBULINEMIA.Matous J.; Lee H.-P.; Opat S. ; Hrom J.; Kliman D.; Marlton P.; Liu P.; Du C.; Lussier A.; Zhang J.; Guo H.; Treon S.
27-Feb-2026RESULTS from the PHASE 1 STUDY of the NOVEL BCL2 INHIBITOR SONROTOCLAX (SONRO) in COMBINATION with ZANUBRUTINIB (ZANU) for RELAPSED/REFRACTORY (R/R) CLL/SLL SHOW DEEP and DURABLE RESPONSES.Opat S. ; Anderson M.A.; Tedeschi A.; Verner E.; Lasica M.; Arbelaez A.; Stilgenbauer S.; Browett P.; Leitch S.; Barca E.G.; Shadman M.; Hou J.-Z.; Eradat H.; Shuo M.A.; Westerman D.; Fang Y.; Hilger J.; Patel S.; Ding W.; Guo H.; Tam C.
27-Feb-2026ECONOMIC EVALUATION of PROPHYLACTIC IMMUNOGLOBULIN VERSUS PROPHYLACTIC ANTIBIOTICS in HEMATOLOGICAL MALIGNANCIES: RESULTS from the RATIONAL FEASIBILITY TRIAL.De Albornoz S.C.; Higgins A.; Petrie D.; Irving A.; Fanning L.; Weinkove R.; Crispin P.; Dendle C. ; Gilbertson M. ; Keegan A.; Johnston A.; Pepperell D.; Pullon H.; Reynolds J.; Van Tonder T.; Trotman J.; Waters N.; Wellard C.; Weston H.; Morrissey C.O.; Wood E.; McQuilten Z. 
27-Feb-2026A PHASE 1B STUDY of the MENIN-KMT2A INHIBITOR JNJ-75276617 in COMBINATION with VENETOCLAX and AZACITIDINE in RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA with ALTERATIONS in KMT2A or NPM1.Wei A.H.; Searle E.; Aldoss I.; Pierola A.A.; Alonso-Dominguez J.M.; Curtis M.; Daskalakis N.; Della Porta M.G.; Dohner H.; D'Souza A.; Dugan J.P.; Esteve J.; Exum M.; Fathi A.T.; Fedele P.L. ; Ferrante L.; Gaj S.; Diaz A.G.; Guttke C.; Gyan E.; Hiebert B.; Jabbour E.; Jentzsch M.; Konopleva M.; Kronke J.; Kwon M.C.; Lomas O.; Mancini V.; Mantzaris I.; Martinelli G.; O'Nions J.; Packman K.; Papayannidis C.; Philippar U.; Recher C.; Rollig C.; Salamero O.; Sanga M.; Sauer T.; Tucker T.; Vallet N.; Vyas P.; Garciaz S.
27-Feb-2026Acute Lower GI Bleeding: Risk Factors for Readmission and Inpatient Endoscopic Necessity.Fujino S.; Arachchi A.; Narasimhan V.; Suhardja T.; Tay Y.K.; Lim J.; Saranasuriya C.; Nguyen T.C.; Teoh W.; Chouhan H.
27-Feb-2026PRELIMINARY SAFETY and ANTILEUKEMIC ACTIVITY of SONROTOCLAX (BGB-11417), A POTENT and SELECTIVE BCL2 INHIBITOR, in TREATMENT-NAIVE PATIENTS with ACUTE MYELOID LEUKEMIA.Shortt J. ; Tan S.; Leitch S.; Liang J.M.C.; Fong C.Y.; Ramanathan S.; Li Q.; Montesinos P.; Dinardo C.; Zhong J.; Chan W.; Li R.; Zernovak O.; Agarwal A.; Wei A.H.
27-Feb-2026DEFINITION and USE of BULKY DISEASE in LYMPHOMA CARE: A STUDY from the AUSTRALASIAN LYMPHOMA and RELATED DISEASES REGISTRY (LARDR).Chung E.; Wang L. ; Wellard C.; Barraclough A.; Campbell B.; Chong G.; Di Ciaccio P.; Gregory G. ; Hapgood G.; Johnston A.; Tam C.; Opat S. ; Wood E.; McQuilten Z. ; Hawkes E.A.
Collection's Items (Sorted by Submit Date in Descending order): 161 to 180 of 6734
< previous   next >

Date issued